EUVIMEDEUVIMED entdecken
Crossref

Inhibition of Innate Immune Allorecognition Using Nanobiologics Effectively Overturns Ongoing T Cell Mediated Allograft Rejection 2305425

Megan Stasik, Khodor Abou-Daya, Paroma Banerjee, Geoffrey Camirand, Hussein El Bourji, Spiros Giannoutsos, Kristina Heins, Canxiang Lin, Jordi Ochando, Andressa Pena, Brianna Robinson, Steven Sanders und 3 weitere

The Journal of Immunology · 01.08.2026 · 215 (Supplement_1)

DOI: 10.1093/jimmun/vkag141.1292 ↗

Kurz gefasst

Fachartikel in der Zeitschrift The Journal of Immunology, online erschienen am 28.07.2026. Verfasst von Megan Stasik und 14 weiteren Autor:innen.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Acute T cell mediated rejection (TCMR) episodes are inadequately controlled by rejection treatment and impede long-term survival. Given that TCMR is driven by innate allorecognition memory (Allo-IMem), we investigated whether specifically inhibiting Allo-IMem using nanobiologics would overturn TCMR.

Methods

WT B6 recipients of Balb/c islet allografts were left untreated and then treated at the peak of TCMR (days 7-12) with innate immune cell specific high-density lipoprotein nanobiologics. Nanobiologics were either unloaded (control; U-NB) or loaded with the mTOR inhibitor rapamycin (mTORi-NB; 5mg/kg) and compared to free rapamycin (Rapa; 5mg/kg).

Results

We uncovered that Allo-IMem signals through mTOR, and unlike Rapa treatment, mTORi-NB inhibits Allo-IMem compared to U-NB. Remarkably, mTORi-NB treatment at the peak of TCMR overturned rejection in 90% of recipients and was therapeutically advantageous over Rapa treatment. scRNA-seq analysis of graft-infiltrating innate cells (day 10) demonstrated that mTORi-NB inhibited cell cycle, glycolysis, and type I/II interferon signaling, and promoted TGF-β signaling pathways, compared to U-NB. Multiphoton intravital microscopy of islet allografts on day 10 revealed that mTORi-NB significantly reduced both the dynamics (speed and distance traveled) and intracellular Ca+ signaling in effector T cells, compared to U-NB. Mechanistically, mTORi-NB significantly reduced the antigenic presentation capacity of graft-infiltrating innate cells compared to U-NB. In addition, both graft infiltrating effector T cell proliferation and IFNγ+ numbers were significantly decreased with mTORi-NB compared to U-NB.

Conclusion

Taken together, we demonstrate that inhibiting Allo-IMem using innate cell specific mTORi-NB effectively overturns TCMR, thus providing a novel targeted therapeutic treatment for acute rejection in transplant patients. Funding Source NIH U01 U01AI132758 (GC)↑, Thomas E. Starzl Postdoctoral Fellowship in Transplantation Biology (HB)↑ Topic Categories Transplantation Immunology (TRAN)

Zitieren

APA

Stasik, M., Abou-Daya, K., Banerjee, P., Camirand, G., Bourji, H. E., Giannoutsos, S., Heins, K., Lin, C., Ochando, J., Pena, A., Robinson, B., Sanders, S., Tang, Z., Teunissen, A., & Venkataramanan, R. (2026). Inhibition of Innate Immune Allorecognition Using Nanobiologics Effectively Overturns Ongoing T Cell Mediated Allograft Rejection 2305425. The Journal of Immunology, 215(Supplement_1). https://doi.org/10.1093/jimmun/vkag141.1292

Vancouver

Stasik M, Abou-Daya K, Banerjee P, Camirand G, Bourji HE, Giannoutsos S, et al. Inhibition of Innate Immune Allorecognition Using Nanobiologics Effectively Overturns Ongoing T Cell Mediated Allograft Rejection 2305425. The Journal of Immunology. 2026;215(Supplement_1). doi:10.1093/jimmun/vkag141.1292

BibTeX
@article{Stasik2026,
  author = {Stasik, Megan and Abou-Daya, Khodor and Banerjee, Paroma and Camirand, Geoffrey and Bourji, Hussein El and Giannoutsos, Spiros and Heins, Kristina and Lin, Canxiang and Ochando, Jordi and Pena, Andressa and Robinson, Brianna and Sanders, Steven and Tang, Zhouqi and Teunissen, Abraham and Venkataramanan, Raman},
  title = {Inhibition of Innate Immune Allorecognition Using Nanobiologics Effectively Overturns Ongoing T Cell Mediated Allograft Rejection 2305425},
  journal = {The Journal of Immunology},
  year = {2026},
  volume = {215},
  number = {Supplement_1},
  doi = {10.1093/jimmun/vkag141.1292}
}
Kostenlos starten →